Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by (1,020)

Items 301–400 of 1,020

1. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
   Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan A. Żurawski, Juliana Janoski De Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan et al. · 2021 · ESMO Open
2. Neurologic complications of immune checkpoint inhibitors
   Alexandra M. Haugh, John C. Probasco, Douglas Buckner Johnson · 2020 · Expert Opinion on Drug Safety
3. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma
   Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Maria Arance, Jan Willem B. de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay et al. · 2022 · Journal of Clinical Oncology
4. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies
   Luc Magré, Monique M. A. Verstegen, Sonja I. Buschow, Luc J. W. van der Laan, Maikel Petrus Peppelenbosch, Jyaysi Desai · 2023 · Journal for ImmunoTherapy of Cancer
5. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
   Anthony Richard Cillo, Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl R. Kunning, Cindy Sander, Elizabeth A. Rush, Arivarasan D. Karunamurthy, Ryan Campbell Massa, Anjali Rohatgi et al. · 2024 · Cell
6. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
   Dovedi, Simon J., Elder, Matthew J., Yang, Chunning, Sitnikova, Suzanne I., Irving, Lorraine, Hansen, Anna, Hair, James, Jones, Des C., Hasani, Sumati, Wang, Bo et al. · 2021 · Cancer Discovery
7. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
   Margaret K. Callahan, Harriet M. Kluger, Michael Andrew Postow, Neil Howard Segal, Alexander M. Lesokhin, Michael B. Atkins, John M. Kirkwood, Suba Krishnan, Rafia Bhore, Christine E. Horak et al. · 2017 · Journal of Clinical Oncology
8. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
   Yoshiyuki Nakamura · 2019 · Frontiers in Medicine
9. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
   Karen A. Autio, Valentina Boni, Rachel W. Humphrey, Aung Naing · 2019 · Clinical Cancer Research
10. Immunotherapy for Glioblastoma: Current Progress and Challenges
    Miranda W. Yu, Daniela F. Quail · 2021 · Frontiers in Immunology
11. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
    Nicola Gaynor, John Paul Crown, Denis Martin Collins · 2020 · Seminars in Cancer Biology
12. Biomarkers of response to PD-1 pathway blockade
    Hanxiao Li, P. Anton van der Merwe, Shivan Sivakumar · 2022 · British Journal of Cancer
13. A comprehensive review of immune checkpoint inhibitors for cancer treatment
    Md Aslam Hossain · 2024 · International Immunopharmacology
14. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
    Pok Fai Wong, Wei Wei, James William Smithy, Balázs Ács, Maria I Toki, Kim Blenman, Daniel A. Zelterman, Harriet M. Kluger, David L. Rimm · 2019 · Clinical Cancer Research
15. Current landscape and future directions of bispecific antibodies in cancer immunotherapy
    Jing Wei, Yueyao Yang, Gang Wang, Ming Liu · 2022 · Frontiers in Immunology
16. Current issues and perspectives in PD-1 blockade cancer immunotherapy
    Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo · 2020 · International Journal of Clinical Oncology
17. Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
    Rik Jasper Verheijden, Anne Maria May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Marye J. Boers‐Sonderen, Jacobus J. M. van der Hoeven, Geke A.P. Hospers et al. · 2020 · Clinical Cancer Research
18. LAG3’s Enigmatic Mechanism of Action
    Colin G. Graydon, Shifa Mohideen, Keith Raymond Fowke · 2021 · Frontiers in Immunology
19. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
    Hao Chen, Wei Chong, Qian Wu, Yueliang Yao, Min Mao, Xin Wang · 2019 · Frontiers in Immunology
20. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
    Yinghao Zhao, Wei Yang, Yuanyuan Huang, Ranji Cui, Xiangyan Li, Bingjin Li · 2018 · Cellular Physiology and Biochemistry
21. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
    Lingjiao Meng, Haotian Wu, Jiaxiang Wu, Ping’an Ding, Jinchen He, Meixiang Sang, Lihua Liu · 2024 · Cell Death and Disease
22. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
    Abdulaali R. Almutairi, Ali McBride, Marion Kimball Slack, Brian L. Erstad, Ivo L Abraham · 2020 · Frontiers in Oncology
23. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
    Ari M. Vanderwalde, Shay L. Bellasea, Kari Lynn Kendra, Nikhil I. Khushalani, Katie Marie Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances A. Collichio, Jeffrey Alan Sosman, Alexandra P. Ikeguchi et al. · 2023 · Nature Medicine
24. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
    Ny, Lars, Jespersen, Henrik, Karlsson, Joakim, Alsén, Samuel, Filges, Stefan, All-Eriksson, Charlotta, Andersson, Bengt, Carneiro, Ana, Helgadottir, Hildur, Levin, Max et al. · 2021 · Nature Communications
25. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
    Jian Qiao, Zhida Liu, Chunbo Dong, Yan Luan, Anli Zhang, Casey Moore, Kai Fu, Jianjian Peng, Yang Wang, Zhenhua Ren et al. · 2019 · Cancer Cell
26. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
    Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher M. Attwood, Sebastiano Battaglia, Saby George, Gurkamal S. Chatta, Igor J. Puzanov et al. · 2021 · Nature Communications
27. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
    Eléonora De Martin, Jean‐Marie Michot, Olivier Rosmorduc, Catherine Guettier, Didier Samuel · 2020 · JHEP Reports
28. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
    Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria G. Atkinson, Michael Schenker, Jacopo Pigozzo, Helen J Gogas, Stéphane Dalle, Nicolás Meyer et al. · 2022 · Journal of Clinical Oncology
29. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
30. New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986–2016
    Juliana Berk-Krauss, Jennifer Stein, Jeffrey S. Weber, David Polsky, Alan C. Geller · 2020 · American Journal of Public Health
31. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
    Robert I. Haddad, Kevin Joseph Harrington, Makoto Tahara, Robert Louis Ferris, Maura L. Gillison, Jérôme Fayette, Amaury Daste, P. Koralewski, Bogdan A. Żurawski, Miren Taberna et al. · 2022 · Journal of Clinical Oncology
32. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
    Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig R. Underhill, Matteo Salvatore Carlino, Louise A. Jackett, Caroline Lum, Clare L. Scott, Adnan M. Nagrial et al. · 2020 · Clinical Cancer Research
33. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
    Robin Reschke, Jovian Yu, Blake A. Flood, Emily F. Higgs, Ken Hatogai, Thomas Frank Gajewski · 2021 · Journal for ImmunoTherapy of Cancer
34. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
    Carina N. Owen, Xue Li Bai, Gaik Tin Quah, Serigne Lo, Clara Allayous, Sophia Callaghan, Clara Martínez-Vila, Roslyn Wallace, Prachi Bhave, Irene L. M. Reijers et al. · 2021 · Annals of Oncology
35. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
    Lili Mao, Zhonghui Qi, Li Zhang, Jun Guo, Lu Si · 2021 · Frontiers in Immunology
36. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
    Mark Anthony Perazella, Anushree C. Shirali · 2019 · Kidney International
37. Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
    Shipra Gandhi, Manu Raj Pandey, Kristopher M. Attwood, Wenyan Ji, Agnieszka Katarzyna Witkiewicz, Erik S. Knudsen, Cheryl L. Allen, Joseph Dennis Tario, Paul K. Wallace, Carlos D. Cedeno et al. · 2020 · Clinical Cancer Research
38. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
    Samuel I. Kim, Christopher R. Cassella, Katelyn T. Byrne · 2021 · Frontiers in Immunology
39. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
    Siwei Zheng, Wenwen Wang, Lesang Shen, Yao Yao, Wenjie Xia, Chao Ni · 2024 · Experimental Hematology and Oncology
40. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
    Peter M.K. Westcott, Francesc Muyas, Haley Hauck, Olivia C. Ghirardelli Smith, Nathan J. Sacks, Zackery A. Ely, Alex M. Jaeger, William M. Rideout, Daniel Zhang, Arjun J. Bhutkar et al. · 2023 · Nature Genetics
41. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
    Knox, Tessa, Sahakian, Eva, Banik, Debarati, Hadley, Melissa, Palmer, Erica, Noonepalle, Satish, Kim, Jennifer, Powers, John, Gracia-Hernandez, Maria, Oliveira, Vasco et al. · 2019 · Scientific Reports
42. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
    Jarushka Naidoo, Catherine Murphy, Michael B. Atkins, Julie Renee Brahmer, Stéphane Champiat, David Feltquate, Lee M. Krug, Javid J. Moslehi, Maria Catherine Pietanza, Joanne Riemer et al. · 2023 · Journal for ImmunoTherapy of Cancer
43. The treatment of advanced melanoma: Current approaches and new challenges
    Andrea Boutros, Elena Croce, Marco Ferrari, Riccardo Gili, Giulia Massaro, Riccardo Marconcini, Luca Arecco, Enrica T. Tanda, Francesco Spagnolo · 2024 · Critical Reviews in Oncology/Hematology
44. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
    Trujillo, Jonathan A., Luke, Jason J., Zha, Yuanyuan, Segal, Jeremy P., Ritterhouse, Lauren L., Spranger, Stefani, Matijevich, Karen, Gajewski, Thomas F. · 2019 · Journal for ImmunoTherapy of Cancer
45. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
    Brenda De Keersmaecker, Sofie Claerhout, Javier Carrasco, Isabelle Bar, Jurgen Corthals, Sofie Wilgenhof, Bart Neyns, Kris Thielemans · 2020 · Journal for ImmunoTherapy of Cancer
46. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
    Paolo A. Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina Venetia Long, Rachel E. Sanborn, Vanna Chiarion‐Sileni, Brigitte Dréno, Stéphane Dalle, Dirk Schadendorf et al. · 2023 · Journal of Clinical Oncology
47. Advances in immune checkpoint inhibitors for bone sarcoma therapy
    Pichaya Thanindratarn, Dylan C. Dean, Scott D. Nelson, Francis John Hornicek, Zhenfeng Duan · 2019 · Journal of bone oncology
48. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
    Stefania Gori, Alessandro Inno, Lorenzo Belluomini, Paolo Bocus, Zeno Bisoffi, Antonio Dello Russo, Guido Arcaro · 2019 · Critical Reviews in Oncology/Hematology
49. Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
    Inês Pires da Silva, Serigne Lo, Camelia Y. J. Quek, Maria Gonzalez, Matteo Salvatore Carlino, Georgina Venetia Long, Alexander Maxwell Menzies · 2019 · Cancer
50. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
    Yang Liu, Pan Zheng · 2019 · Trends in Pharmacological Sciences
51. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non–small cell lung cancer (NSCLC)
    Ricciuti, Biagio, Jones, Greg, Severgnini, Mariano, Alessi, Joao V, Recondo, Gonzalo, Lawrence, Marissa, Forshew, Tim, Lydon, Christine, Nishino, Mizuki, Cheng, Michael et al. · 2021 · Journal for ImmunoTherapy of Cancer
52. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
    Vanessa A. Evans, Renée Marije van der Sluis, Ajantha E. Solomon, Ashanti Dantanarayana, Catriona M. McNeil, Roger J Garsia, Sarah Palmer, Rémi Fromentin, Nicolas Chomont, Rafick‐Pierre Sékaly et al. · 2018 · AIDS
53. Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
    Jin U. Kang, Chao Zhang, Wen‐Zhao Zhong · 2021 · 癌症：英文版
54. Barriers and opportunities in pancreatic cancer immunotherapy
    Yixin Ju, Dongzhi Xu, Miao-Miao Liao, Yutong Sun, Wen-dai Bao, Fan Yao, Li Ma · 2024 · npj Precision Oncology
55. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
    Chun‐Bing Chen, Ming-Ying Wu, Chau Yee Ng, Chun‐Wei Lu, Jennifer Wu, Pei‐Han Kao, Chan‐Keng Yang, Meng‐Ting Peng, Chen‐Yang Huang, Wen-Cheng Chang et al. · 2018 · Cancer Management and Research
56. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
    Qiang Su, Emily C. Zhu, Jingbo Wu, Teng Li, Yanli Hou, Diya Wang, Zu‐Hua Gao · 2019 · Frontiers in Immunology
57. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
    Simona Serratì, Michele Guida, R. Fonte, Simona De Summa, Sabino Strippoli, Rosa Maria Iacobazzi, Alessandra Quarta, Ivana De Risi, Gabriella Guida, Angelo Paradiso et al. · 2022 · Molecular Cancer
58. Targeted Therapy and Immunotherapy for Melanoma in Japan
    Kenjiro Namikawa, Naoya Yamazaki · 2019 · Current Treatment Options in Oncology
59. Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis
    Kikkie Poels, Mandy M. T. van Leent, C. Boutros, Hubert Tissot, Séverine Roy, Anu E. Meerwaldt, Yohana C. Toner, Myrthe E. Reiche, Pascal J. H. Kusters, Tsveta S. Malinova et al. · 2020 · JACC CardioOncology
60. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
    Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, Nicola Tumino, Paola Vacca, Lorenzo Moretta · 2020 · Cancers
61. A gut microbial signature for combination immune checkpoint blockade across cancer types
    Gunjur, Ashray, Shao, Yan, Rozday, Timothy, Klein, Oliver, Mu, Andre, Haak, Bastiaan W., Markman, Ben, Kee, Damien, Carlino, Matteo S., Underhill, Craig et al. · 2024 · Nature Medicine
62. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells
    Suresh Bugide, Michael R. Green, Narendra Wajapeyee · 2018 · Proceedings of the National Academy of Sciences
63. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
    Muhammad Babar Khan, Zhihong Zhao, Sumbal Arooj, Yuxiang Fu, Guixiang Liao · 2020 · Frontiers in Immunology
64. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
    Juliya Fisher, Nathalie C. Zeitouni, Weijia Fan, Faramarz H. Samie · 2019 · Journal of the American Academy of Dermatology
65. NRAS mutant melanoma: Towards better therapies
    Tijana Randic, Ines Kozar, Christiane Margue, Jochen Sven Utikal, Stephanie Kreis · 2021 · Cancer Treatment Reviews
66. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
    Aaron C. Tan, Louise Emmett, Serigne Lo, V. Liu, Rony Kapoor, Matteo Salvatore Carlino, Alexander David Guminski, Georgina Venetia Long, Alexander Maxwell Menzies · 2018 · Annals of Oncology
67. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab
    Andrew L. Lin, Philip Jonsson, Viviane S. Tabar, Jonathan T. Yang, John J. Cuaron, K. Beal, Marc A. Cohen, Michael Andrew Postow, Marc K. Rosenblum, Jinru Shia et al. · 2018 · The Journal of Clinical Endocrinology & Metabolism
68. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
    Simon Wisnovsky, Leonhard Möckl, Stacy Alyse Malaker, Kayvon Pedram, Gaelen T. Hess, Nicholas McIlvain Riley, Melissa Anne Gray, Benjamin A. H. Smith, Michael Cory Bassik, W. E. Moerner et al. · 2021 · Proceedings of the National Academy of Sciences
69. Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma
    Aleksey K. Molodtsov, Nikhil Khatwani, Jennifer L. Vella, Kathryn A. Lewis, Yanding Zhao, Jichang Han, Delaney E. Sullivan, Tyler G. Searles, Nicholas K. Preiss, Tamer Basel Shabaneh et al. · 2021 · Immunity
70. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
    Carole Achard, Abera Surendran, Marie-Ève Wedge, Guy Ungerechts, John Cameron Bell, Carolina S. Ilkow · 2018 · EBioMedicine
71. Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings
    Hummel, Horst-Dieter, Kufer, Peter, Grüllich, Carsten, Seggewiss-Bernhardt, Ruth, Deschler-Baier, Barbara, Chatterjee, Manik, Goebeler, Maria-Elisabeth, Miller, Kurt, de Santis, Maria, Loidl, Wolfgang et al. · 2021 · Immunotherapy
72. Cutaneous Melanoma—A Review in Detection, Staging, and Management
    Rebecca Ivy Hartman, Jennifer Y. Lin · 2018 · Hematology/Oncology Clinics of North America
73. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
    James W. Opzoomer, Dominika Sosnowska, Joanne E. Anstee, James F. Spicer, James N. Arnold · 2019 · Frontiers in Immunology
74. The New Era of Immunotherapy in Gastric Cancer
    Shogo Takei, Akihito Kawazoe, Kohei Shitara · 2022 · Cancers
75. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
    Su Yin Lim, Elena Shklovskaya, Jenny Lee, Bernadette Pedersen, Ashleigh Stewart, Zizhen Ming, Mal Irvine, Brindha Shivalingam, Robyn P.M. Saw, Alexander Maxwell Menzies et al. · 2023 · Nature Communications
76. Enhancing immunotherapy with tumour-responsive nanomaterials
    Stephen W. Linderman, Louis B. DeRidder, Lucía Sanjurjo, Michael Bonner Foote, Marı́a José Alonso, Ameya R. Kirtane, Róbert Langer, Giovanni Traverso · 2025 · Nature Reviews Clinical Oncology
77. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
    Simpson, Rebecca C., Shanahan, Erin R., Scolyer, Richard A., Long, Georgina V. · 2023 · Nature Reviews Clinical Oncology
78. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
    Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia Maria Tsimberidou, Joseph Elan Grossman, Michael S. Gordon, Breelyn Ann Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian et al. · 2024 · Nature Medicine
79. Why do patients with cancer die?
    Adrienne Ann Boire, Katy Burke, Thomas R. Cox, Theresa A. Guise, Mariam Jamal‐Hanjani, Tobias Janowitz, Rosandra Natasha Kaplan, Rebecca J. Lee, Charles Swanton, Matthew G. Vander Heiden et al. · 2024 · Nature reviews. Cancer
80. Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
    Bailey, Christopher M., Liu, Yan, Liu, Mingyue, Du, Xuexiang, Devenport, Martin, Zheng, Pan, Liu, Yang, Wang, Yin · 2022 · Journal of Clinical Investigation
81. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
    Frank Friedrich Gellrich, Marc Schmitz, Stefan Beissert, Friedegund Elke Meier · 2020 · Journal of Clinical Medicine
82. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy
    Jichang Han, Yanding Zhao, Keisuke Shirai, Aleksey K. Molodtsov, Fred Kolling, Jan L. Fisher, Peisheng Zhang, Shaofeng Yan, Tyler G. Searles, Justin M. Bader et al. · 2021 · Nature Cancer
83. In vivo dendritic cell reprogramming for cancer immunotherapy
    Ervin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannová, Xavier Catena, Nadezhda Rotankova, Charlotte Veser, Michał Rudnik et al. · 2024 · Science
84. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Devin C. Dressman, Antonios Papanicolau‐Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo et al. · 2018 · Journal for ImmunoTherapy of Cancer
85. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
    Chuckran, Christopher A, Liu, Chang, Bruno, Tullia C, Workman, Creg J, Vignali, Dario AA · 2020 · Journal for ImmunoTherapy of Cancer
86. Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
    Zappasodi, Roberta, Budhu, Sadna, Hellmann, Matthew D., Postow, Michael A., Senbabaoglu, Yasin, Manne, Sasikanth, Gasmi, Billel, Liu, Cailian, Zhong, Hong, Li, Yanyun et al. · 2018 · Cancer Cell
87. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
    Italia Falcone, Fabiana Conciatori, Chiara Bazzichetto, Gianluigi Ferretti, Francesco Cognetti, Ludovica Ciuffreda, Michèle Milella · 2020 · Cancers
88. The gut microbiome: what the oncologist ought to know
    Karla A. Lee, Marilan Luong, Heather May Shaw, Paul Nathan, Veronique A. Bataille, Tim D. Spector · 2021 · British Journal of Cancer
89. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy
    Laura Ann Huppert, Michael D. Green, Luke Kim, Christine Chow, Yan Leyfman, ADIL I. DAUD, James Lee · 2021 · Cellular and Molecular Immunology
90. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
    Sungjune Kim, Evan John Wuthrick, Dukagjin M. Blakaj, Zeynep Eroglu, Claire F. Verschraegen, Ram Thapa, Matthew N. Mills, Khaled Nabil Dibs, Casey L. Liveringhouse, Jeffery Scott Russell et al. · 2022 · The Lancet
91. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
    Wensi Zhao, Jun Lei, Shaobo Ke, Yuan Chen, Jiping Xiao, Li Wang, Li Wang, Yiping Ren, Mohammed Alnaggar, Hu Qiu et al. · 2023 · EClinicalMedicine
92. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
    Bishma Jayathilaka, Farah Mian, Fanny Franchini, George Au‐Yeung, Maarten J. IJzerman · 2024 · British Journal of Cancer
93. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma
    Ting Yan, Heyang Cui, Yong Zhou, Bin Juan Yang, Pengzhou Kong, Yingchun Zhang, Yiqian Liu, Bin Wang, Yikun Cheng, Jiayi Li et al. · 2019 · Nature Communications
94. Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi, Kazuhiko Nakagawa · 2019 · International Journal of Clinical Oncology
95. Kidney Cancer
    Nivedita Chowdhury, Charles G. Drake · 2020 · Urologic Clinics of North America
96. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
    Pai, Chien-Chun Steven, Huang, John T., Lu, Xiaoqing, Simons, Donald M., Park, Chanhyuk, Chang, Anthony, Tamaki, Whitney, Liu, Eric, Roybal, Kole T., Seagal, Jane et al. · 2019 · Immunity
97. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
    Marie‐Andrée Forget, Cara Haymaker, Kenneth R. Hess, Yuzhong Jeff Meng, Caitlin A. Creasy, Tatiana V. Karpinets, Orenthial J. Fulbright, Jason Roszik, Scott Eric Woodman, Young Uk Kim et al. · 2018 · Clinical Cancer Research
98. Role of the microbiota in response to and recovery from cancer therapy
    Stephen J. Blake, Yochai Wolf, Ben Boursi, David John Lynn · 2023 · Nature reviews. Immunology
99. French Endocrine Society guidance on endocrine side effects of immunotherapy
    Castinetti, F, Albarel, F, Archambeaud, F, Bertherat, J, Bouillet, B, Buffier, P, Briet, C, Cariou, B, Caron, Ph, Chabre, O et al. · 2019 · Endocrine Related Cancer
100. Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges
     Nancy Alice Nixon, Normand Blais, Scott Ernst, Christian Kollmannsberger, Gwyn D. Bebb, Marcus Otho Butler, Michael Smylie, Sunil Verma · 2018 · Current Oncology